1.15
price down icon10.16%   -0.13
after-market Handel nachbörslich: 1.15
loading
Schlusskurs vom Vortag:
$1.28
Offen:
$1.28
24-Stunden-Volumen:
196.14K
Relative Volume:
0.65
Marktkapitalisierung:
$74.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.86M
KGV:
-1.0268
EPS:
-1.12
Netto-Cashflow:
$-55.66M
1W Leistung:
-17.27%
1M Leistung:
-23.33%
6M Leistung:
-53.06%
1J Leistung:
-75.22%
1-Tages-Spanne:
Value
$1.15
$1.291
1-Wochen-Bereich:
Value
$1.15
$1.39
52-Wochen-Spanne:
Value
$1.15
$5.09

Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile

Name
Firmenname
Acumen Pharmaceuticals Inc
Name
Telefon
925-368-8508
Name
Adresse
427 PARK ST., CHARLOTTESVILLE
Name
Mitarbeiter
52
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-13
Name
Neueste SEC-Einreichungen
Name
ABOS's Discussions on Twitter

Vergleichen Sie ABOS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ABOS
Acumen Pharmaceuticals Inc
1.15 74.50M 0 -64.86M -55.66M -1.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.31 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
684.87 75.07B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
622.61 37.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
243.53 31.79B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
111.56 27.34B 3.30B -501.07M 1.03B -2.1146

Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-07-26 Eingeleitet Citigroup Buy
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-07-20 Fortgesetzt BofA Securities Buy
2023-05-18 Eingeleitet Cantor Fitzgerald Overweight
2022-07-15 Eingeleitet BTIG Research Buy
2022-06-30 Eingeleitet H.C. Wainwright Buy
2022-01-21 Hochstufung BofA Securities Neutral → Buy
2021-07-26 Eingeleitet BofA Securities Neutral
2021-07-26 Eingeleitet Credit Suisse Outperform
2021-07-26 Eingeleitet Stifel Buy
2021-07-26 Eingeleitet UBS Buy
Alle ansehen

Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten

pulisher
Feb 26, 2025

ABOS stock touches 52-week low at $1.28 amid market challenges - Investing.com

Feb 26, 2025
pulisher
Feb 26, 2025

ABOS stock touches 52-week low at $1.28 amid market challenges By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference - Victoria Advocate

Feb 26, 2025
pulisher
Feb 17, 2025

Acumen stock touches 52-week low at $1.54 amid market challenges - MSN

Feb 17, 2025
pulisher
Feb 16, 2025

Acumen Pharmaceuticals CEO O'Connell sells shares worth $20,102 - MSN

Feb 16, 2025
pulisher
Feb 16, 2025

Acumen Pharmaceuticals COO Barton Russell sells shares worth $4,692 - MSN

Feb 16, 2025
pulisher
Feb 15, 2025

SG Americas Securities LLC Grows Stock Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

Feb 15, 2025
pulisher
Feb 12, 2025

ABOS stock touches 52-week low at $1.31 amid market challenges - MSN

Feb 12, 2025
pulisher
Feb 11, 2025

ABOS stock touches 52-week low at $1.31 amid market challenges By Investing.com - Investing.com South Africa

Feb 11, 2025
pulisher
Feb 05, 2025

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat

Feb 05, 2025
pulisher
Feb 04, 2025

Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results - cnhinews.com

Feb 04, 2025
pulisher
Feb 02, 2025

JPMorgan Chase & Co. Has $156,000 Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

Feb 02, 2025
pulisher
Feb 02, 2025

Barclays Cuts Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $26.00 - Defense World

Feb 02, 2025
pulisher
Jan 31, 2025

ABOS stock touches 52-week low at $1.52 amid market challenges - Investing.com India

Jan 31, 2025
pulisher
Jan 31, 2025

ABOS stock touches 52-week low at $1.52 amid market challenges By Investing.com - Investing.com South Africa

Jan 31, 2025
pulisher
Jan 31, 2025

Acumen Pharmaceuticals chief medical officer sells $5,118 in shares - MSN

Jan 31, 2025
pulisher
Jan 29, 2025

Acumen Pharmaceuticals chief legal officer sells shares worth $5,434 - MSN

Jan 29, 2025
pulisher
Jan 24, 2025

Matt Zuga Sells 28,902 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 12,619 Shares - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Acumen Pharmaceuticals CFO sells shares totaling $56,619 - MSN

Jan 24, 2025
pulisher
Jan 24, 2025

Promising US Penny Stocks To Consider In January 2025 - Simply Wall St

Jan 24, 2025
pulisher
Jan 24, 2025

Analysts Set Expectations for ABOS FY2025 Earnings - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

Acumen Pharmaceuticals CFO sells shares totaling $56,619 By Investing.com - Investing.com South Africa

Jan 23, 2025
pulisher
Jan 23, 2025

Acumen Pharmaceuticals CEO O'Connell sells shares worth $20,102 By Investing.com - Investing.com Canada

Jan 23, 2025
pulisher
Jan 23, 2025

Brokers Offer Predictions for ABOS FY2025 Earnings - MarketBeat

Jan 23, 2025
pulisher
Jan 23, 2025

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock Holdings Lifted by Barclays PLC - Defense World

Jan 23, 2025
pulisher
Jan 20, 2025

Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Expands By 9.1% - Defense World

Jan 20, 2025
pulisher
Jan 17, 2025

Acumen stock touches 52-week low at $1.54 amid market challenges By Investing.com - Investing.com South Africa

Jan 17, 2025
pulisher
Jan 10, 2025

ABOS stock touches 52-week low at $1.68 amid market challenges - Investing.com

Jan 10, 2025
pulisher
Jan 09, 2025

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings - The Manila Times

Jan 09, 2025
pulisher
Jan 09, 2025

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of - The Bakersfield Californian

Jan 09, 2025
pulisher
Jan 09, 2025

Acumen's Alzheimer's Drug Shows Promise: Phase 1 Trial Reveals Strong Safety Profile, Plaque Reduction - StockTitan

Jan 09, 2025
pulisher
Jan 08, 2025

Acumen Pharmaceuticals CFO Zuga Matt sells $24,366 in stock By Investing.com - Investing.com Australia

Jan 08, 2025
pulisher
Jan 08, 2025

Acumen Pharmaceuticals' chief legal officer sells $20,505 in stock By Investing.com - Investing.com Australia

Jan 08, 2025
pulisher
Jan 08, 2025

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Purchased by Geode Capital Management LLC - Defense World

Jan 08, 2025
pulisher
Jan 08, 2025

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Bought by Barclays PLC - Defense World

Jan 08, 2025

Finanzdaten der Acumen Pharmaceuticals Inc-Aktie (ABOS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Acumen Pharmaceuticals Inc-Aktie (ABOS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Zuga Matt
CFO & Chief Business Officer
Jan 21 '25
Sale
1.60
4,364
6,986
260,646
OConnell Daniel Joseph
Chief Executive Officer
Jan 21 '25
Sale
1.59
12,619
20,102
667,488
Meisner Derek M
Chief Legal Officer & Corp Sec
Jan 21 '25
Sale
1.59
3,418
5,435
161,127
Barton Russell
Chief Operating Officer
Jan 21 '25
Sale
1.61
2,914
4,692
136,117
Siemers Eric
Chief Medical Officer
Jan 21 '25
Sale
1.59
3,219
5,118
170,298
$76.29
price down icon 6.45%
$22.96
price up icon 1.23%
$33.86
price up icon 0.65%
$19.13
price down icon 7.54%
biotechnology ONC
$245.53
price down icon 9.67%
$111.56
price down icon 1.20%
Kapitalisierung:     |  Volumen (24h):